

Name of product	Daunorubicin infusion. Aseptically prepared from licensed sterile starting ma
Concentration	Concentration range typically up to 1mg/ml in 250ml infusion bags in accord with the national dose banding tables. The Daunorubicin concentrate should be added to the bag without withdraw equivalent volume of Sodium Chloride 0.9% w/v Infusion unless withdrawal infusion fluid is required to accomodate the total dose.
Diluent	Sodium Chloride 0.9% w/v
Volume	250ml
Final container	Non-PVC e.g. polyolefin infusion bag with additive port cover. Ideally infusion bag design will incorporate self sealing giving port to minimurity risks associated with accidental spillage during administration.
Starting materials	Licensed Daunorubicin powder for reconstitution for injection. Licensed Water for Injections Licensed Sodium Chloride 0.9% w/v infusion bags
abelling	Labelling must be compliant with the principles of labelling for safety and th General specification on unlicensed medicines.Tall Man lettering must be u the drug name.
Label sample	An example label is provided below stating the minimum requirements only label format is not restrictive and suppliers can use their preferred layout):- DAUNOrubicin xxxmg in xxxml Sodium Chloride 0.9% w/v For Intravenous Infusion Infuse the entire contents of the bag Store in a Refrigerator at 2-8°C Protect From Light Expiry: dd/mm/yyyy BN: XXXXXXXX Keep out of the reach and sight of children Manufacturer's details MS XXXXXX <i>Caution Cytotoxic: Handle with care</i>
Batch Number	All products will have a unique batch identification number
Latex status of - components - manufacturing process	All materials and manufacturing processes will be latex free or clearly labell not.
Stability	Stability studies should conform to the Standard Protocol for deriving and assessment of stability of Aseptic preparations (small molecules) published NHS Pharmaceutical QA Committee (4th Edition, April 2017).